Related Experiment Videos
[Mechanisms of action of class III anti-arrhythmia agents]
1Laboratoire de pharmacologie, Faculté de médecine, Lille.
Insights
New antiarrhythmic drugs target potassium currents to prolong cardiac action potentials. Understanding their complex effects is key to developing safer, more effective treatments with reduced proarrhythmic risks.
Area of Science:
- Pharmacology
- Cardiac Electrophysiology
Context:
- Vaughan-Williams Class III antiarrhythmics prolong cardiac action potential duration.
- This prolongation can be achieved by modulating ion currents, with newer drugs focusing on potassium channels.
Purpose:
- To explore the mechanisms of Class III antiarrhythmic agents.
- To understand the factors influencing their proarrhythmic and antiarrhythmic effects.
- To define the profile of an ideal Class III antiarrhythmic drug.
Summary:
- Class III agents prolong the refractory period by altering sodium, calcium, or potassium currents.
- Newer agents selectively block membrane potential-regulated potassium channels (Ito, IK, IK1).
- This action prolongs ventricular repolarization, potentially causing reverse frequency-dependence and a positive inotropic effect.
Impact:
- Class III effects can lead to proarrhythmia, including torsades de pointes, favored by bradycardia and electrolyte imbalances.
- Early afterdepolarizations are experimentally induced, suggesting a cellular trigger.
- Comprehending these effects aids in designing drugs with optimal efficacy and minimal proarrhythmic risk.
Abstract:
Vaughan-Williams class III antiarrhythmic agents act mainly by prolonging the duration of the cardiac action potential and, thus, the refractory period. This effect may be obtained: 1) by increasing the inward sodium or calcium currents, which may lead to an intracellular calcium overload and induce a very proarrhythmic situation, or 2) by decreasing the outward potassium currents, the objective of the new class III antiarrhythmic drugs under development. They selectively block one or several potassium channels regulated by the membrane potential (transient outward current Ito, delayed rectifying current IK and rectifying inward current IK1). Under physiological conditions the blockade of potassium channels regulated by a ligand (for example, ATP-dependent) does not lead to a class III effect. Prolongation of ventricular repolarisation is accompanied by a slowing of the heart rate and a positive inotropic effect. It is attenuated by rapid rhythms and amplified by slow rhythms: this is the reverse frequency-dependent phenomenon. However, normal frequency dependence (or "use-dependence") has been reported with the ionic channel, this paradox apparently being related to the complexity of the relations between the relative contributions of the ionic currents of repolarisation and their modulation by the heart rate. The class III effect confers a proarrhythmic potential and may lead to torsades de pointes, favorised by bradycardia, hypokalaemia and hypomagnesaemia. Experimentally, it favorises early after depolarisations which are presumed to be the cellular trigger event. The comprehension of factors influencing the antiarrhythmic and proarrhythmic class III effects has led to the establishment of a pharmacological profile of the "ideal" drug conferring the least proarrhythmic risk and the best efficacy.